{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000020","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.621613+00:00","generated_at":"2026-06-17T21:56:20.368099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspira Women's Health FY2022 revenue $8.2M (+20% YoY); Q4 cash burn $7.1M","bullets":["Full-year revenue $8.2M, up 20% from $6.8M; OvaSuite volume 21,423 units (+23% YoY).","Gross margin improved to 53% (FY) vs 45% in 2021; Q4 gross margin 57% vs 55%.","Cash and short-term investments $13.6M at year-end; 2023 cash utilization guided $16-19M.","OvaWatch launched late 2022; March 2023 coverage secured from major national payer.","EndoCheck (endometriosis blood test) development on track for 2023 launch target."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000020","json":"https://secwatch.observer/filing/0000926617-23-000020.json","markdown":"https://secwatch.observer/filing/0000926617-23-000020.md","text":"https://secwatch.observer/filing/0000926617-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/awh-20230322x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:56:20.368099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b6afd4f08f8c3fe2e1e8ebeae9fb97644417367","claim":"Aspira Women's Health Inc. reported the three months ended December 31, 2022 results: revenue $2.2 million.","evidence_excerpt":"Total revenue for the three months ended December 31, 2022 was $2.2 million, an increase of 16% compared to $1.9 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$2.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7b251b21262b4e490d4204c4c06f1fbe81a80175","claim":"Aspira Women's Health Inc. reported the year ended December 31, 2022 results: revenue $8.2 million.","evidence_excerpt":"Total revenue was $8.2 million for the year ended December 31, 2022, an increase of 20% compared to $6.8 million for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$8.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}